ReviewActa diabetologica2026
Maturity onset diabetes of the young in pregnancy: management, treatment and neonatal outcomes-a systematic review.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maturity Onset Diabetes of the Young (MODY) is a type of genetically inherited diabetes. As it generally arises in early adulthood, it can affect pregnant women with significant neonatal outcomes. Our study aimed to conduct a systematic review on pregnancy management and outcomes of all subtypes of MODY, browsing the Cochrane, EMBASE and PubMed databases to find clinical studies on the topic. They were last searched on June 29, 2025. The inclusion criteria for our review were: published articles, available in their full-text version, about MODY, reporting data about its management during pregnancy and neonatal outcomes, in English language, specifying therapeutic approaches used. The exclusion criteria were: study designs reported below, written in other languages, not present in above mentioned databases. The risk of bias was assessed through the ROBIS tool. Our systematic review analyzed data on 1408 live births of 1183 pregnant women, and found specific guidelines for the management of pregnant women affected with GCK-MODY and HNF1A-MODY, but none on rarer subtypes. Thus, indications on pregnancy management and outcomes of rarer MODYs were identified through an additional literature review, and its findings were summarized in Table 1. Our systematic review was limited by the lack of data on rarer subtypes of MODY and the specific keywords and databases selected. However, our work lays an important step in the direction of much-needed clinical data and recommendations in treating rare MODY subtypes during pregnancy, towards healthy offspring delivery and growth. A further literature review was carried out to identify any data on other subtypes of MODY and their neonatal outcomes, and the findings were summarized in Table 1. No funding was needed to carry out the present systematic review. PROSPERO registration number: CRD420251062633.
Indexed as
Identifiers
42329282What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.